ReviewFuture medicinal chemistry2016
Sphingolipids as targets for treatment of fungal infections.
Review in Future medicinal chemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 86 citations in OpenAlex.
- Fungal Sphingolipids: Biosynthesis Pathways, Structural Features and Biological Functions.Journal of fungi (Basel, Switzerland) · 2026Review
- Peptides in plant-microbe interactions: Functional diversity and pharmacological applications.Cell surface (Amsterdam, Netherlands) · 2025Review
- The antimicrobial activity of ETD151 defensin is dictated by the presence of glycosphingolipids in the targeted organisms.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Regulation of cellular and systemic sphingolipid homeostasis.Nature reviews. Molecular cell biology · 2024Review
- Antifungal Activity of Disalt of Epipyrone A fromJournal of fungi (Basel, Switzerland) · 2024Article
- Article
- Sphingolipid diversity in Candida auris: unraveling interclade and drug resistance fingerprints.FEMS yeast research · 2024Article
- Bacteria and fungi of the lung: allies or enemies?Frontiers in pharmacology · 2024Review
- Harnessing inter-kingdom metabolic disparities at the human-fungal interface for novel therapeutic approaches.Frontiers in molecular biosciences · 2024Article
- Dual species sphingosine-1-phosphate lyase inhibitors to combine antifungal and anti-inflammatory activities in cystic fibrosis: a feasibility study.Scientific reports · 2023Article
- Role of sphingolipids in the host-pathogen interaction.Biochimica et biophysica acta. Molecular and cell biology of lipids · 2023Article
- Genetic Characterization of the Acidic and Neutral Glycosphingolipid Biosynthetic Pathways inMicroorganisms · 2023Article
- Article
- Pandemic Response Box® library as a source of antifungal drugs against Scedosporium and Lomentospora species.PloS one · 2023Article
- Systematic Metabolic Profiling IdentifiesmSystems · 2022Article
- Article
- Protective interaction of human phagocytic APC subsets withFrontiers in immunology · 2022Article
- Identification of a novel SPT inhibitor WXP-003 by docking-based virtual screening and investigation of its anti-fungi effect.Journal of enzyme inhibition and medicinal chemistry · 2021Article
- Identification of Promising Antifungal Drugs againstJournal of fungi (Basel, Switzerland) · 2021Article
- Sphingolipid Inhibitors as an Alternative to Treat Candidiasis Caused by Fluconazole-Resistant Strains.Pathogens (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
Invasive fungal infections have significantly increased in the last few decades. Three classes of drugs are commonly used to treat these infections: polyenes, azoles and echinocandins. Unfortunately each of these drugs has drawbacks; polyenes are toxic, resistance against azoles is emerging and echinocandins have narrow spectrum of activity. Thus, the development of new antifungals is urgently needed. In this context, fungal sphingolipids have emerged as a potential target for new antifungals, because their biosynthesis in fungi is structurally different than in mammals. Besides, some fungal sphingolipids play an important role in the regulation of virulence in a variety of fungi. This review aims to highlight the diverse strategies that could be used to block the synthesis or/and function of fungal sphingolipids.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.